Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 21, Issue 3, Pages 138-140
http://dx.doi.org/10.1155/2010/296760
Case Report

Ceftobiprole: First Reported Experience in Osteomyelitis

A MacDonald1 and G Dow2

1Northumberland Centre for Medical Education and Research, Canada
2Section of Infectious Diseases, The Moncton Hospital, Horizon Health Network – Zone 1, Moncton, New Brunswick, Canada

Copyright © 2010 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [3 citations]

The following is the list of published articles that have cited the current article.

  • Claudio D'Amario, Edoardo Carretto, Paolo Fazii, Domenico D'Antonio, Vincenzo Savini, Carlo Crescenzi, Daniela Astolfi, Roberta Marrollo, Andrea Balbinot, Claudio D'Amario, Edoardo Carretto, Paolo Fazii, Domenico D'Antonio, Vincenzo Savini, Carlo Crescenzi, Daniela Astolfi, Roberta Marrollo, and Andrea Balbinot, “Vitek2 may deduce false susceptibility to cefixime in Staphylococcus,” Journal Of Medical Microbiology, vol. 61, no. 9, pp. 1344–1345, 2012. View at Publisher · View at Google Scholar
  • Karolyn S. Horn, Robert C. Glowacki, Larry H. Danziger, and Keith A. Rodvold, “Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA,” Expert Opinion on Drug Metabolism and Toxicology, vol. 13, no. 4, pp. 463–472, 2017. View at Publisher · View at Google Scholar
  • Eric Senneville, “Antibacterial Treatment in Diabetic Foot Infections,” Frontiers in Diabetes, vol. 26, pp. 167–183, 2017. View at Publisher · View at Google Scholar